CAS 51037-30-0|Acipimox
Introduction：Basic information about CAS 51037-30-0|Acipimox, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.
| Common Name | Acipimox | ||
|---|---|---|---|
| CAS Number | 51037-30-0 | Molecular Weight | 154.123 |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 539.0±45.0 °C at 760 mmHg |
| Molecular Formula | C6H6N2O3 | Melting Point | 177-180 °C |
| MSDS | ChineseUSA | Flash Point | 279.8±28.7 °C |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | 5-methyl-4-oxidopyrazin-4-ium-2-carboxylic acid |
|---|---|
| Synonym | More Synonyms |
Acipimox BiologicalActivity
| Description | Acipimox is a niacin derivative used as a hypolipidemic agent.Target: Acipimox is a niacin derivative used as a hypolipidemic agent. It is used in low doses and may have less marked adverse effects, although it is unclear whether the recommended dose is as effective as are standard doses of nicotinic acid. Acipimox inhibits the production of triglycerides by the liver and the secretion of VLDL, which leads indirectly to a modest reduction in LDL and increase in HDL. Long-term administration is associated with reduced mortality, but unwanted effects limit its clinical use. Adverse effects include flushing (associated with Prostaglandin D2), palpitations, and GI disturbances. Flushing can be reduced by taking aspirin 20-30 min before taking Acipimox. High doses can cause disorders of liver function, impair glucose tolerance and precipitate gout. From Wikipedia. |
|---|---|
| Related Catalog | Signaling Pathways >>Others >>OthersNatural Products >>AlkaloidResearch Areas >>Cardiovascular Disease |
| References | [1]. http://en.wikipedia.org/wiki/Acipimox |
Chemical & Physical Properties
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 539.0±45.0 °C at 760 mmHg |
| Melting Point | 177-180 °C |
| Molecular Formula | C6H6N2O3 |
| Molecular Weight | 154.123 |
| Flash Point | 279.8±28.7 °C |
| Exact Mass | 154.037842 |
| PSA | 75.65000 |
| LogP | -1.38 |
| Vapour Pressure | 0.0±1.5 mmHg at 25°C |
| Index of Refraction | 1.608 |
| InChIKey | DJQOOSBJCLSSEY-UHFFFAOYSA-N |
| SMILES | Cc1cnc(C(=O)O)c[n+]1[O-] |
| Storage condition | 2-8°C |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Oral
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 3500 mg/kg
- TOXIC EFFECTS :
- Biochemical - Metabolism (Intermediary) - lipids including transport
- REFERENCE :
- EJMCA5 European Journal of Medicinal Chemistry--Chimie Therapeutique. (Editions Scientifiques Elsevier, 29 rue Buffon, F-75005, Paris, France) V.9- 1974- Volume(issue)/page/year: 15,157,1980
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H319 |
| Precautionary Statements | P305 + P351 + P338 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xi: Irritant; |
| Risk Phrases | R36 |
| Safety Phrases | S26 |
| RIDADR | NONH for all modes of transport |
| RTECS | UQ2453000 |
| HS Code | 2942000000 |
Customs
| HS Code | 2933990090 |
|---|---|
| Summary | 2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Articles30
More Articles| Kinetics and utilization of lipid sources during acute exercise and acipimox. Am. J. Physiol. Endocrinol. Metab. 307(2) , E199-208, (2014) Overweight is associated with abnormalities of lipid metabolism, many of which are reversed by exercise. We investigated the impact of experimental antilipolysis and acute exercise on lipid kinetics a... | |
| The lowering of hepatic fatty acid uptake improves liver function and insulin sensitivity without affecting hepatic fat content in humans. Am. J. Physiol. Endocrinol. Metab. 295(2) , E413-9, (2008) Lipolysis may regulate liver free fatty acid (FFA) uptake and triglyceride accumulation; both are potential causes of insulin resistance and liver damage. We evaluated whether 1) systemic FFA release ... | |
| ECG-triggered 18F-fluorodeoxyglucose positron emission tomography imaging of the rat heart is dramatically enhanced by acipimox. Eur. J. Nucl. Med. Mol. Imaging 37(9) , 1745-50, (2010) 18F-Fluorodeoxyglucose (FDG) imaging, provided by current positron emission tomography (PET) systems dedicated to small animals,might provide a precise functional assessment of the left ventricle (LV)... |
Synonyms
| 5-methyl-2-pyrazinoic-4-oxide |
| 2-Pyrazinecarboxylic acid, 5-methyl-, 4-oxide |
| 2-Carboxy-5-methylpyrazine 4-oxide,5-Methylpyrazinecarboxylic acid 4-oxide |
| 5-Carboxy-2-methylpyrazine 1-oxide |
| 5-methyl-4-oxy-pyrazine-2-carboxylic acid |
| 5-methylpyrazine-2-carboxylic acid 4-oxide |
| 2-carboxy-5-methylpyrazine 4-oxide |
| Acipimox |
| K-9321 |
| Olbetam |
| 5-Methylpyrazinecarboxylic acid 4-oxide |
| 5-Methyl-2-pyrazinecarboxylic acid 4-oxide |
| 2-methyl-5-pyrazinecarboxylic acid 1-oxide |
| Olbemox |
| EINECS 256-928-3 |
| T6N DNJ AO B1 EVQ |
| MFCD00865757 |
